Advertisement

Canadian Journal of Public Health

, Volume 90, Issue 5, pp 293–294 | Cite as

Preparing for Influenza Epidemics and Pandemics in the New Millennium

  • Theresa W. S. Tam
Editorial / Éditorial
  • 1 Downloads

Se préparer aux épidémies et aux pandémies de grippe du prochain millénaire

Bibliographie/References

  1. 1.
    Meltzer MI, Cox NJ, Fukuda K. The economic impact of pandemic influenza in the United States: Priorities for intervention. Emerg Infect Dis 1999;5(5):659–71.CrossRefGoogle Scholar
  2. 2.
    Yuen KY, Chan PK, Peiris M, et al. Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet 1998;351(9101):467–71.CrossRefGoogle Scholar
  3. 3.
    Mounts AW, Kwong H, Izurieta HS, et al. Case-control study of risk factors for avian influenza A (H5N1) disease, Hong Kong, 1997. J Infect Dis 1999;180(2):505–8.CrossRefGoogle Scholar
  4. 4.
    Claas EC, de Jong JC, van Beek R, et al. Human influenza virus A/Hong/Kong/156/97 (H5N1) infection. Vaccine 1998;16(9-10):977–78.CrossRefGoogle Scholar
  5. 5.
    Snacken R, Kendal AP, Haahein LR, Wood JM. The next influenza pandemic: Lessons from Hong Kong, 1997. Emerg Infect Dis 1999;5(2):195–203.CrossRefGoogle Scholar
  6. 6.
    Buck P, Herman S, Scott C, et al. Influenza in Canada 1997–1998 season. Can Commun Dis Rep 1998;24(1):169–76.PubMedGoogle Scholar
  7. 7.
    Hampson AW, Cox NJ. Global surveillance for pandemic influenza: Are we prepared? In: Brown LE, Hampson AW, Wester RG (Eds.), Options for the Control of Influenza III. Amsterdam, the Netherlands: Elsevier Science Publishers, 1996;50–59.Google Scholar
  8. 8.
    Peiris M, Yuen KY, Leung CW, et al. Human infection with influenza H9N2. Lancet 1999;354(9182):916–17.CrossRefGoogle Scholar
  9. 9.
    Li S, Liu C, Klimov A, et al. Recombinant influenza A virus vaccines for the pathogenic human A/Hong Kong/97 (H5N1) viruses. J Infect Dis 1999;179(5):1132–38.CrossRefGoogle Scholar
  10. 10.
    Belshe RB, Mendelman PM, Treanor J, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children. N Engl J Med 1998;338(20):1405–12.CrossRefGoogle Scholar
  11. 11.
    National Advisory Committee on Immunization. Statement on influenza vaccine for the 1999–2000 season. Can Commun Dis Rep 1999;25(ACS-2):1–16.Google Scholar
  12. 12.
    Monto AS, Fleming DM, Henry D, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. J Infect Dis 1999;180(2):254–61.CrossRefGoogle Scholar
  13. 13.
    The MIST Study Group. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. Lancet 1998;352(9144):1877–81.CrossRefGoogle Scholar
  14. 14.
    Monto AS, Robinson DP, Herlocher ML, et al. Zanamivir in the prevention of influenza among healthy adults: A randomized controlled trial. JAMA 1999;282:31–35.CrossRefGoogle Scholar

Copyright information

© The Canadian Public Health Association 1999

Authors and Affiliations

  • Theresa W. S. Tam
    • 1
  1. 1.Division of Respiratory Diseases, Laboratory Centre for Disease Control, Bureau of Infectious DiseasesHealth CanadaCanada

Personalised recommendations